The narrative presents plant-based HMO production as a disruptive innovation with the potential to democratize access to these high-value biomolecules. The strongest version of this argument highlights the scalability and cost advantages of plants over microbial fermentation, as well as the untapped potential of HMOs beyond infant formula. Totality Biosciences’ approach leverages existing agricultural infrastructure, which could accelerate adoption and reduce costs—a compelling proposition for a...